Announcement

Eric Chow & Co. in Association with Commerce & Finance Law Offices (“Tongshang Hong Kong”) represented Transtech Optelecom Science Holdings Limited (“Transtech”) in its transfer of listing from GEM to the Main Board of the Hong Kong Stock Exchange (“HKEx”) (HKSE: 9963.HK) on 5 November 2020.

Transtech is a company based in Hong Kong and principally engaged in manufacturing and sales of optical fibres, optical fibre cables, optical cable cores and other related products. It has been listed on GEM since July 2017. HKEx amended its listing rules in early 2018 and imposed more stringent requirements on transfer of listing applications from GEM to the Main Board. As an Eligible Issuer, Transtech made use of the transitional transfer of listing arrangement under Appendix 28 of the Listing Rules and successfully transferred its listing to the Main Board of HKEx on 5 November 2020.

Tongshang Hong Kong acted as the Hong Kong legal adviser of Transtech in its transfer of listing, and was responsible for the drafting of the transfer of listing announcement and other related work for the transfer of listing and provided full range and high-quality legal services to its client in the transfer of listing project. The outstanding work attitude and professionalism have been recognised by its client in the project.

Commerce & Finance Law Offices always strive to provide comprehensive, full-service and high-quality legal services to its corporate and private clients. The establishment of Tongshang Hong Kong was a stepping stone to achieve the goal. With the expansion into the Hong Kong legal market, we believe we are able to provide a more comprehensive and high-quality legal services, especially in the IPOs and capital markets transactions in both Hong Kong and PRC markets.

Eric Chow & Co. in Association with Commerce & Finance Law Offices (“Tongshang Hong Kong”) represented Ganglong China Property Group Limited (“Ganglong China Property”) in its listing on the Main Board of the Hong Kong Stock Exchange (HKSE: 06968.HK) on 15 July 2020.

Ganglong China Property is an established property developer in the Yangtze River Delta Region focusing on the development and sales of properties predominantly for residential use mixed with accompanying ancillary facilities, such as retail units, carparks and ancillary areas. Headquartered in Shanghai, Ganglong China Property has established an active presence and a strategic regional coverage in the Yangtze River Delta Region, one of the most economically prosperous and vibrant regions in the PRC, which is expected to enjoy healthy economic growth continuously according to the Industry Report.

Tongshang Hong Kong acted as the Hong Kong legal adviser to the sponsor and underwriters of the IPO of Ganglong China Property and was responsible for the drafting of prospectus. Tongshang Hong Kong has provided high-quality and tailor-made legal solutions to the sponsor and underwriters throughout the listing process.

Tongshang is renowned for its expertise in the PRC property sector IPOs and Ganglong China Property is yet another PRC property developer IPO completed by Tongshang, our recent experiences include Zhenro Properties, Zhongliang Holdings, DaFa Properties, Redsun Properties, Dexin China and Sinic Holdings.

The successful listing of Ganglong China Property has demonstrated the professionalism and extensive experience of our team. Commerce & Finance Law Offices always strive to maintain a very good relationship with their clients and provide the best legal services to them. In order to provide clients with a comprehensive and “one-stop shop” PRC and Hong Kong legal services, the Tongshang Hong Kong office was set up. The expansion into the Hong Kong legal market has enabled us to provide a full legal service on advising both Hong Kong and PRC laws in IPOs and other capital markets transactions.

Commerce & Finance Law Offices (“Tongshang”), together with Eric Chow & Co., its Hong Kong associated law firm (“Tongshang Hong Kong”), jointly represented Immunotech Biopharm Ltd (“Immunotech Biopharm”) in its listing on the Main Board of the Hong Kong Stock Exchange (HKSE: 06978.HK) on 10 July 2020. The Hong Kong Public Offering was very well received by the investors and recorded approximately 259 times oversubscription. Immunotech Biopharm’s listing is yet another project collaborated and completed by Tongshang Beijing and Tongshang Hong Kong, in which we proudly provided a “one-stop shop” PRC and Hong Kong legal services to our client.

Immunotech Biopharm is a leading cellular immunotherapy biopharmaceutical company in China focusing on the research, development, and commercialisation of T cell immunotherapy over 13 years. According to the Frost & Sullivan Report, EAL® - Immunotech Biopharm's Core Product Candidate is the first cellular immunotherapy product in China approved for entry into a Phase II clinical trial, and, the only that had been approved for application in a Phase II clinical trial for solid tumour.

Tongshang and Tongshang Hong Kong acted as the issuer’s PRC and Hong Kong legal adviser in this Hong Kong IPO respectively and have provided high-quality and tailor-made legal solutions to the issuer throughout the listing process.

Tongshang has been renowned for its experiences in Biotech and Healthcare sector and Immunotech Biopharm is another Hong Kong biotech listing successfully completed by Tongshang, previous experiences include Ascletis Pharma, Hua Medicine, Innovent Biologics, CanSino Biologics, Mabpharm Limited, Sinomab Bioscience, Alphamab Oncology, Innocare Pharma, Akeso and Peijia Medical.

Tongshang tops the chart of PRC Legal Advisers in Biotech sector in 2020 by completing four Hong Kong IPOs for pre-revenue biotech companies so far, namely, Innocare Pharma, Akeso, Peijia Medical and Immunotech. In another milestone, Tongshang Hong Kong is also the first Hong Kong associated law firm of a PRC firm to successfully complete a Hong Kong listing under Chapter 18A of the Hong Kong Listing Rules.

The successful listing of Immunotech Biopharm has demonstrated the professionalism, extensive experience and great collaboration between Tongshang’s China and Hong Kong teams. Tongshang always strive to maintain a very good relationship with their clients and provide the best legal services to them. In order to provide clients with a comprehensive and “one-stop shop” PRC and Hong Kong legal services, Tongshang Hong Kong office was set up. The expansion into the Hong Kong legal market has enabled us to provide a full legal service on advising both Hong Kong and PRC laws in IPOs and other capital markets transactions.

Eric Chow & Co. in Association with Commerce & Finance Law Offices (“Tongshang Hong Kong”) represented Maike Tube Industry Holdings Limited (“Maike Tube”) in its listing on the Main Board of the Hong Kong Stock Exchange (HKSE: 01553.HK) on 18 December 2019. Maike Tube also marked the first manufacturing company in Jinan that is listed in Hong Kong.

Maike Tube is principally engaged in manufacturing and selling of standard pre-fabricated pipe nipple products and steel pipe products. It also designs and supplies a range of assembled piping systems to its customers. Maike Tube operates two production plants in Jinan and a production plant in Dong Nai Province, Vietnam. Maike Tube’s customers are based in Mainland China and more than 35 countries overseas. According to Frost & Sullivan Report, it ranked first in the PRC standard prefabricated pipe nipple industry in terms of export value by tons in 2018.

Tongshang Hong Kong acted as the Hong Kong legal adviser of the IPO of Maike Tube and has provided high-quality and tailor-made legal solutionsto the issuer throughout the listing process.

The successful listing of Maike Tube has demonstrated the professionalism and extensive experience of our team. Commerce & Finance Law Offices always strive to maintain a very good relationship with their clients and provide the best legal services to them. In order to provide clients with a comprehensive and “one-stop shop” PRC and Hong Kong legal services, the Tongshang Hong Kong office was set up. The expansion into the Hong Kong legal market has enabled us to provide a full legal service on advising both Hong Kong and PRC laws in IPOs and other capital markets transactions.